These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9333520)

  • 1. Summer recess might squeeze FDA reform bill.
    Fox JL
    Nat Biotechnol; 1997 Aug; 15(8):715. PubMed ID: 9333520
    [No Abstract]   [Full Text] [Related]  

  • 2. Senate FDA reform bill--good news for the pharmaceutical industry?
    Jack DB
    Mol Med Today; 1995 Oct; 1(7):300. PubMed ID: 9415166
    [No Abstract]   [Full Text] [Related]  

  • 3. How FDA approves biotechnology drugs.
    Manuel SM; Piascik P
    Am Pharm; 1995 May; NS35(5):14-5. PubMed ID: 7611131
    [No Abstract]   [Full Text] [Related]  

  • 4. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 5. Confronting the future of the FDA.
    Serafini MW
    Natl J (Wash); 1996 Dec; 28(50):2704-5. PubMed ID: 10163877
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA reform signed into law. Food and Drug Administration.
    James JS
    AIDS Treat News; 1997 Dec; (No 284):6-7. PubMed ID: 11364915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More ado about cloning.
    Nat Biotechnol; 1998 Mar; 16(3):219. PubMed ID: 9527995
    [No Abstract]   [Full Text] [Related]  

  • 8. Sandoz sues FDA over delay in first biogeneric approval.
    Fox JL
    Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotech industry struggles with generics approval.
    Knight J
    Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent developments help the defense of drug companies in 10b-5 cases.
    Salpeter AN; Hutchins H
    Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711
    [No Abstract]   [Full Text] [Related]  

  • 12. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 13. The FDA and "privatization"--the drug approval process.
    Rutherford EM
    Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA vs. free speech over drug promotions.
    Anderson C
    Nature; 1991 Dec; 354(6353):421. PubMed ID: 1749421
    [No Abstract]   [Full Text] [Related]  

  • 15. A balancing act.
    Nat Biotechnol; 2009 Mar; 27(3):209. PubMed ID: 19270650
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA reform: new Senate bill. Food and Drug Administration.
    James JS
    AIDS Treat News; 1995 Nov; (no 235):7-8. PubMed ID: 11363048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An industry imperiled by regulatory bottlenecks.
    Naughton G
    Nat Biotechnol; 2001 Aug; 19(8):709-10. PubMed ID: 11479550
    [No Abstract]   [Full Text] [Related]  

  • 19. Will politics sidetrack FDA reform?
    Gatty B
    Formulary; 1995 Aug; 30(8):476, 475. PubMed ID: 10151736
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulatory evaluation of biotechnology drugs: current trends in the United States.
    Sobel S
    Bioprocess Technol; 1991; 13():499-511. PubMed ID: 1367148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.